Global Primary Sclerosing Cholangitis Treatment Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Primary Sclerosing Cholangitis Treatment Market Overview

• 1.1 Product Overview and Scope of Primary Sclerosing Cholangitis Treatment
• 1.2 Classification of Primary Sclerosing Cholangitis Treatment by Types
  • 1.2.1 Global Primary Sclerosing Cholangitis Treatment Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Types in 2018
  • 1.2.3 Liver Transplantation Operation
  • 1.2.4 UDCA Drugs
  • 1.2.5 PSC Drugs
• 1.3 Global Primary Sclerosing Cholangitis Treatment Market by Application
  • 1.3.1 Global Primary Sclerosing Cholangitis Treatment Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Hospital
  • 1.3.3 Clinics
  • 1.3.4 Other
• 1.4 Global Primary Sclerosing Cholangitis Treatment Market by Regions
  • 1.4.1 Global Primary Sclerosing Cholangitis Treatment Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Primary Sclerosing Cholangitis Treatment Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Primary Sclerosing Cholangitis Treatment Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Primary Sclerosing Cholangitis Treatment Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Primary Sclerosing Cholangitis Treatment Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Primary Sclerosing Cholangitis Treatment Status and Prospect (2014-2024)
• 1.5 Global Market Size of Primary Sclerosing Cholangitis Treatment (2014-2024)

2 Company Profiles

• 2.1 Allergan
  • 2.1.1 Business Overview
  • 2.1.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Allergan Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Epic Pharma
  • 2.2.1 Business Overview
  • 2.2.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Mylan
  • 2.3.1 Business Overview
  • 2.3.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Mylan Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Glenmark
  • 2.4.1 Business Overview
  • 2.4.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Glenmark Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Daewoong Pharmaceutical
  • 2.5.1 Business Overview
  • 2.5.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 Impax Laboratories
  • 2.6.1 Business Overview
  • 2.6.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Lannett
  • 2.7.1 Business Overview
  • 2.7.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Lannett Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Dr. Falk Pharma
  • 2.8.1 Business Overview
  • 2.8.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Teva Pharmaceuticals
  • 2.9.1 Business Overview
  • 2.9.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 Mitsubishi Tanabe Pharma
  • 2.10.1 Business Overview
  • 2.10.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.11 Gilead Sciences
  • 2.11.1 Business Overview
  • 2.11.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.11.2.1 Product A
    • 2.11.2.2 Product B
  • 2.11.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.12 NGM Biopharmaceuticals
  • 2.12.1 Business Overview
  • 2.12.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.12.2.1 Product A
    • 2.12.2.2 Product B
  • 2.12.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.13 Bruschettini
  • 2.13.1 Business Overview
  • 2.13.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.13.2.1 Product A
    • 2.13.2.2 Product B
  • 2.13.3 Bruschettini Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.14 Durect Corporation
  • 2.14.1 Business Overview
  • 2.14.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.14.2.1 Product A
    • 2.14.2.2 Product B
  • 2.14.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.15 Intercept Pharmaceuticals
  • 2.15.1 Business Overview
  • 2.15.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.15.2.1 Product A
    • 2.15.2.2 Product B
  • 2.15.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.16 Acorda Therapeutics
  • 2.16.1 Business Overview
  • 2.16.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.16.2.1 Product A
    • 2.16.2.2 Product B
  • 2.16.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.17 Shanghai Pharma
  • 2.17.1 Business Overview
  • 2.17.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.17.2.1 Product A
    • 2.17.2.2 Product B
  • 2.17.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.18 Conatus Pharmaceuticals
  • 2.18.1 Business Overview
  • 2.18.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.18.2.1 Product A
    • 2.18.2.2 Product B
  • 2.18.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.19 Shire Plc
  • 2.19.1 Business Overview
  • 2.19.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.19.2.1 Product A
    • 2.19.2.2 Product B
  • 2.19.3 Shire Plc Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.20 Grindeks
  • 2.20.1 Business Overview
  • 2.20.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.20.2.1 Product A
    • 2.20.2.2 Product B
  • 2.20.3 Grindeks Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.21 Sirnaomics
  • 2.21.1 Business Overview
  • 2.21.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.21.2.1 Product A
    • 2.21.2.2 Product B
  • 2.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)
• 2.22 Shenzhen HighTide Biopharmaceuticals
  • 2.22.1 Business Overview
  • 2.22.2 Primary Sclerosing Cholangitis Treatment Type and Applications
    • 2.22.2.1 Product A
    • 2.22.2.2 Product B
  • 2.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2018)

3 Global Primary Sclerosing Cholangitis Treatment Market Competition, by Players

• 3.1 Global Primary Sclerosing Cholangitis Treatment Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Primary Sclerosing Cholangitis Treatment Players Market Share
  • 3.2.2 Top 10 Primary Sclerosing Cholangitis Treatment Players Market Share
• 3.3 Market Competition Trend

4 Global Primary Sclerosing Cholangitis Treatment Market Size by Regions

• 4.1 Global Primary Sclerosing Cholangitis Treatment Revenue and Market Share by Regions
• 4.2 North America Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 4.3 Europe Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 4.5 South America Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)

5 North America Primary Sclerosing Cholangitis Treatment Revenue by Countries

• 5.1 North America Primary Sclerosing Cholangitis Treatment Revenue by Countries (2014-2019)
• 5.2 USA Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 5.3 Canada Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)

6 Europe Primary Sclerosing Cholangitis Treatment Revenue by Countries

• 6.1 Europe Primary Sclerosing Cholangitis Treatment Revenue by Countries (2014-2019)
• 6.2 Germany Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 6.3 UK Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 6.4 France Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 6.5 Russia Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 6.6 Italy Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue by Countries

• 7.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue by Countries (2014-2019)
• 7.2 China Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 7.3 Japan Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 7.4 Korea Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 7.5 India Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)

8 South America Primary Sclerosing Cholangitis Treatment Revenue by Countries

• 8.1 South America Primary Sclerosing Cholangitis Treatment Revenue by Countries (2014-2019)
• 8.2 Brazil Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Primary Sclerosing Cholangitis Treatment by Countries

• 9.1 Middle East and Africa Primary Sclerosing Cholangitis Treatment Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 9.3 UAE Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2014-2019)

10 Global Primary Sclerosing Cholangitis Treatment Market Segment by Type

• 10.1 Global Primary Sclerosing Cholangitis Treatment Revenue and Market Share by Type (2014-2019)
• 10.2 Global Primary Sclerosing Cholangitis Treatment Market Forecast by Type (2019-2024)
• 10.3 Liver Transplantation Operation Revenue Growth Rate (2014-2024)
• 10.4 UDCA Drugs Revenue Growth Rate (2014-2024)
• 10.5 PSC Drugs Revenue Growth Rate (2014-2024)

11 Global Primary Sclerosing Cholangitis Treatment Market Segment by Application

• 11.1 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Application (2014-2019)
• 11.2 Primary Sclerosing Cholangitis Treatment Market Forecast by Application (2019-2024)
• 11.3 Hospital Revenue Growth (2014-2019)
• 11.4 Clinics Revenue Growth (2014-2019)
• 11.5 Other Revenue Growth (2014-2019)

12 Global Primary Sclerosing Cholangitis Treatment Market Size Forecast (2019-2024)

• 12.1 Global Primary Sclerosing Cholangitis Treatment Market Size Forecast (2019-2024)
• 12.2 Global Primary Sclerosing Cholangitis Treatment Market Forecast by Regions (2019-2024)
• 12.3 North America Primary Sclerosing Cholangitis Treatment Revenue Market Forecast (2019-2024)
• 12.4 Europe Primary Sclerosing Cholangitis Treatment Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue Market Forecast (2019-2024)
• 12.6 South America Primary Sclerosing Cholangitis Treatment Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Primary Sclerosing Cholangitis Treatment Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology